Related Experiment Video
Updated: Jul 2, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Deuruxolitinib: New Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. cdi@adis.com.
None:
Deuruxolitinib (LEQSELVI), a deuterated analogue of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib, is being developed by Sun Pharmaceuticals Industries for the treatment of alopecia areata. In July 2024, deuruxolitinib received its first global approval for the treatment of severe alopecia areata in adults in the USA. Additionally, in March 2026, deuruxolitinib received approval in the same indication in the UK. This article summarizes the milestones in the development of deuruxolitinib leading to the approval for severe alopecia areata in adults.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistent Cancers
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Regulation
Therapeutic Drug Monitoring: Overview and Classification
